Granules India
BSE 532482 · ISIN INE101D01020
12 stories, newest first.
- Granules India Ltd-$: promoter acquires ~2.5 crore warrants
- Granules India Ltd-$ promoter buys 9.16% stake, holding rises to 37.39%
- Granules India Ltd-$ promoter sells 6.94% stake, holding falls to 31.08%
- Board meeting on 02 November 2026 to consider Q2 and H1 results ended 30 September 2026
- Incorporates Wholly Owned Foreign Subsidiary in Mexico
- USFDA re-inspection began at Granules' Gagillapur facility, which had received a warning letter in 2025
- Granules India saw intraday recovery after a week of selling, believed linked to a clean-out sale by a large domestic insurance entity
- Paragraph IV certification submitted for Ruxolitinib Extended-Release Tablets ANDA; potential first-to-file eligibility
- Webinar transcript: four growth engines, two sole first-to-file ANDAs, complex generics at 33% of FY26 revenue
- Incorporation of wholly owned foreign subsidiary Triton Farmaceutica do Brasil Ltda in Brazil
- Audio recording of September 29, 2026 webinar uploaded on Granules India website
- IIFL Capital webinar on Sept 29, 2026 with Granules promoter and senior management on transformation journey
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.